Sugi Predict

Sugi Predict / Compounds / SCHEMBL344042

SCHEMBL344042

SCHEMBL344042

Cn1nnc(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ NPC1 O15118 4/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51
▸ RELA Q04206 1/20 0.51
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MAPK1 P28482 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ NR1H2 P55055 1/20 0.47
▸ NR1H3 Q13133 1/20 0.47
▸ PPARA Q07869 1/20 0.46
▸ ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2316723 0.89 NPC1 (0.52) RAB9AL3MBTL1NPC1SMN1; SMN2NFKB1
SCHEMBL8212790 0.87 ACLY (0.53) RAB9AL3MBTL1NPC1SMN1; SMN2NFKB1
SCHEMBL27907618 0.84 ABCG2 (0.62) RAB9AL3MBTL1NPC1SMN1; SMN2NFKB1
SCHEMBL30123049 0.82 TRPM8 (0.40) RAB9AL3MBTL1NPC1SMN1; SMN2NFKB1
SCHEMBL13841588 0.81 NPC1 (0.54) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL22322481 0.81 USP2 (0.47) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL5775 0.81 LTA4H (0.51) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL13846214 0.80 MAPK1 (0.49) RAB9AL3MBTL1NPC1SMN1; SMN2NFKB1
SCHEMBL2611134 0.79 KMT2A (0.54) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL2611131 0.79 LMNA (0.49) RAB9AL3MBTL1NPC1SMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 — — WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 — — US claimed
US-6498180-B1 SUCH AS 2-(3'-HYDROXYMETHYL-2'-CARBOXYCYCLOPROPYL)GLYCINE; MODULATING METABOTROPIC GLUTAMATE RECEPTOR; TREATING DISORDERS OF CENTRAL NERVOUS ELI LILLY AND COMPANY 2002-12-24 — — US claimed
EP-1189873-A1 EXCITATORY AMINO ACID RECEPTOR MODULATORS Lilly, S.A. (ES) 2002-03-27 — — EP claimed
WO-2000075101-A1 EXCITATORY AMINO ACID RECEPTOR MODULATORS LILLY, S.A. (ES) 2000-12-14 — — WO claimed
WO-2023275796-A1 HETEROCYCLIC DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE 3 INHIBITORS NOVARTIS AG (CH) 2023-01-05 — — WO disclosed
US-20220386614-A1 OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME NIHON NOHYAKU CO., LTD. (JP) 2022-12-08 — — US disclosed
US-20200148634-A1 ACLY INHIBITORS AND USES THEREOF Nimbus Artemis, Inc. 2020-05-14 — — US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
EP-2590967-B1 USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS UDC IRELAND LTD (IE) 2019-05-15 — — EP disclosed
US-20190085208-A1 POLISHING COMPOSITION, METHOD FOR PRODUCING SAME, POLISHING METHOD, AND METHOD FOR PRODUCING SUBSTRATE FUJIMI INCORPORATED (JP) 2019-03-21 — — US disclosed
EP-0215739-B1 SYNTHESIS OF BETA-LACTAM COMPOUNDS CIBA-GEIGY AG (CH) 1993-09-01 — — EP disclosed
US-5215997-A Synthesis of beta-lactam compounds CIBA-GEIGY CORPORATION (US) 1993-06-01 — — US disclosed
US-5153315-A Penicilllin deriviatives CIBA-GEIGY CORPORATION (US) 1992-10-06 — — US disclosed
US-4962196-A (3S, 4R)-3,4-trans-disubstituted azetidin-2-one intermediates CIBA-GEIGY CORPORATION (US) 1990-10-09 — — US disclosed
EP-0297042-A1 Substituted penem compounds CIBA-GEIGY AG (CH) 1988-12-28 — — EP disclosed
EP-0233155-A1 Aminoacyloxymethyl compounds CIBA-GEIGY AG (CH) 1987-08-19 — — EP disclosed
EP-0215739-A1 Synthesis of beta-lactam compounds CIBA-GEIGY AG (CH) 1987-03-25 — — EP disclosed
EP-0201459-A1 Acylaminomethyl-penem compounds, their preparation and pharmaceutical formulations containing them CIBA-GEIGY AG (CH) 1986-11-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 RAB9A 1370/4885L3MBTL1 3021/4885NPC1 1062/4885
US-20220386614-A1 OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME BROX, CYP51A1, TBCD RAB9A 2500/4885L3MBTL1 3227/4885NPC1 2380/4885
US-20200148634-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG RAB9A 4051/4885L3MBTL1 2716/4885NPC1 1013/4885
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 RAB9A 20/4885L3MBTL1 2280/4885NPC1 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.